List of insiders holdings for Crinetics Pharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC 10% Owner | 2024-02-14 18:36:08 | 1,667,360 0 | 1,667,360 | Form 13G |
| PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 2024-03-01 20:05:26 | 1,488,703 0 | 1,488,703 | Form 13D |
| 5AM Ventures IV L.P. 5AM Co-Investors IV L.P. 5AM Partners IV LLC ROCKLAGE SCOTT M DIEKMAN JOHN D Schwab Andrew J. Former 10% holder | 2021-02-16 06:31:14 | 1,362,286 0 | 1,362,286 | Form 13G |
| Struthers Richard Scott President & CEO | 2024-05-10 16:57:04 | 273,827 901,805 | 1,175,632 | Form 4 |
| Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner | 2022-02-10 20:21:59 | 382,961 0 | 382,961 | Form 13G |
| Knight Jeff E. Chief Operating Officer | 2024-07-17 17:35:34 | 269,680 0 | 269,680 | Form 4 |
| Madan Ajay Chief Development Officer | 2022-03-02 21:00:35 | 242,395 0 | 242,395 | Form 4 |
| Wilson Marc CFO | 2024-09-30 17:01:16 | 200,092 0 | 200,092 | Form 4 |
| Krasner Alan Seth Chief Medical Officer | 2023-10-19 17:01:13 | 196,683 0 | 196,683 | Form 4 |
| Pizzuti Dana Chief Med and Dev Officer | 2024-10-07 07:55:43 | 167,549 0 | 167,549 | Form 4 |
| Hassard James Chief Commercial Officer | 2024-07-09 18:04:39 | 159,259 0 | 159,259 | Form 4 |
| WIERENGA WENDALL Director | 2024-06-11 16:18:42 | 121,746 0 | 121,746 | Form 4 |
| Betz Stephen F. Chief Scientific Officer | 2024-09-12 16:30:03 | 68,576 0 | 68,576 | Form 4 |
| Freeman Mason Director | 2018-07-17 20:42:55 | 54,711 0 | 54,711 | Form 3 |
| Fust Matthew K Director | 2024-06-11 16:19:49 | 34,436 0 | 34,436 | Form 4 |
| Vivaldi Coelho Rogerio Director | 2024-06-11 16:21:26 | 26,900 0 | 26,900 | Form 4 |
| Bedrosian Camille L Director | 2024-06-11 16:19:10 | 21,900 0 | 21,900 | Form 4 |
| Deardorf Caren Director | 2024-06-11 16:21:55 | 21,900 0 | 21,900 | Form 4 |
| Okey Stephanie Director | 2024-06-11 16:20:49 | 21,900 0 | 21,900 | Form 4 |
| Nichols Weston Director | 2024-06-11 16:20:13 | 21,900 0 | 21,900 | Form 4 |
| Kaldor Stephen W Director | 2020-06-22 16:22:47 | 12,500 0 | 12,500 | Form 4 |
| Nielsen Jack Director | 2019-06-25 16:10:05 | 12,500 0 | 12,500 | Form 4 |
| Vivo Capital VIII LLC Vivo Capital LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. Vivo Opportunity LLC Vivo Opportunity Fund L.P. 10% Owner | 2022-02-11 17:22:24 | 0 0 | 0 | Form 13G |
| Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner | 2022-02-11 17:22:24 | 0 0 | 0 | Form 13G |
| Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. Vivo Opportunity LLC Vivo Opportunity Fund L.P. 10% Owner | 2022-02-11 17:22:24 | 0 0 | 0 | Form 13G |